🚀 VC round data is live in beta, check it out!
Hubei Jumpcan Valuation Multiples
Discover revenue and EBITDA valuation multiples for Hubei Jumpcan and similar public comparables like Zhejiang Huahai, Virbac, Voronoi, J.B. Chemicals & Pharma and more.
Hubei Jumpcan Overview
About Hubei Jumpcan
Hubei Jumpcan Pharmaceutical Co Ltd engages in the research, development, manufacturing, and trading of Chinese traditional medicines, western medicines, daily use chemicals based on Chinese traditional medicines, and Chinese medicine health products in China. It offers Chinese and Western medicines in the areas of pediatrics, gynecology, pneumonology, gastroenterology, and geriatrics. The company also develops Chinese and Western medicines in the areas of detoxification, digestive system, respiratory system, nervous system, anti-infection, cardiovascular, narcotic analgesic, nutrition, musculoskeletal, and hemostasis.
Founded
1997
HQ
Employees
5.0K
Website
Sectors
Financials (LTM)
EV
$2B
Hubei Jumpcan Financials
Hubei Jumpcan reported last 12-month revenue of $901M and EBITDA of $319M.
In the same LTM period, Hubei Jumpcan generated $672M in gross profit, $319M in EBITDA, and $232M in net income.
Revenue (LTM)
Hubei Jumpcan P&L
In the most recent fiscal year, Hubei Jumpcan reported revenue of $1B and EBITDA of $485M.
Hubei Jumpcan expects next 12-month revenue of XXX and NTM EBITDA of XXX
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue | $901M | XXX | $1B | XXX | XXX | XXX |
| Gross Profit | $672M | XXX | $930M | XXX | XXX | XXX |
| Gross Margin | 75% | XXX | 79% | XXX | XXX | XXX |
| EBITDA | $319M | XXX | $485M | XXX | XXX | XXX |
| EBITDA Margin | 35% | XXX | 41% | XXX | XXX | XXX |
| EBIT Margin | 30% | XXX | 32% | XXX | XXX | XXX |
| Net Profit | $232M | XXX | $371M | XXX | XXX | XXX |
| Net Margin | 26% | XXX | 32% | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
Hubei Jumpcan Stock Performance
Hubei Jumpcan has current market cap of $3B, and enterprise value of $2B.
Market Cap Evolution
Hubei Jumpcan's stock price is $3.76.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $2B | $3B | -2.0% | XXX | XXX | XXX | $0.40 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialHubei Jumpcan Valuation Multiples
Hubei Jumpcan trades at 2.2x EV/Revenue multiple, and 6.1x EV/EBITDA.
EV / Revenue (LTM)
Hubei Jumpcan Financial Valuation Multiples
As of April 11, 2026, Hubei Jumpcan has market cap of $3B and EV of $2B.
Equity research analysts estimate Hubei Jumpcan's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Hubei Jumpcan has a P/E ratio of 14.9x.
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $3B | XXX | $3B | XXX | XXX | XXX |
| EV (current) | $2B | XXX | $2B | XXX | XXX | XXX |
| EV/Revenue | 2.2x | XXX | 1.7x | XXX | XXX | XXX |
| EV/EBITDA | 6.1x | XXX | 4.0x | XXX | XXX | XXX |
| EV/EBIT | 7.3x | XXX | 5.2x | XXX | XXX | XXX |
| EV/Gross Profit | 2.9x | XXX | 2.1x | XXX | XXX | XXX |
| P/E | 14.9x | XXX | 9.3x | XXX | XXX | XXX |
| EV/FCF | — | XXX | 6.7x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Hubei Jumpcan Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.
Hubei Jumpcan Margins & Growth Rates
Hubei Jumpcan's revenue in the last 12 month grew by 6%.
Hubei Jumpcan's revenue per employee in the last FY averaged $0.2M, while opex per employee averaged $0.1M for the same period.
Hubei Jumpcan's rule of 40 is 42% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Hubei Jumpcan's rule of X is 50% (created by Bessemer, rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
Hubei Jumpcan Operational Valuation Multiples
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 6% | XXX | (24%) | XXX | XXX | XXX |
| EBITDA Margin | 35% | XXX | 41% | XXX | XXX | XXX |
| EBITDA Growth | 11% | XXX | (36%) | XXX | XXX | XXX |
| Rule of 40 | — | XXX | 42% | XXX | XXX | XXX |
| Bessemer Rule of X | — | XXX | 50% | XXX | XXX | XXX |
| Revenue per Employee | — | XXX | $0.2M | XXX | XXX | XXX |
| Opex per Employee | — | XXX | $0.1M | XXX | XXX | XXX |
| S&M Expenses to Revenue | 35% | XXX | 35% | XXX | XXX | XXX |
| G&A Expenses to Revenue | 6% | XXX | 6% | XXX | XXX | XXX |
| R&D Expenses to Revenue | 5% | XXX | 6% | XXX | XXX | XXX |
| Opex to Revenue | — | XXX | 49% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Hubei Jumpcan Public Comps
See public comps and valuation multiples for other Biopharmaceuticals comps.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| LTM | 2026E | 2027E | LTM | 2026E | 2027E | |
| Zhejiang Huahai | XXX | XXX | XXX | XXX | XXX | XXX |
| Virbac | XXX | XXX | XXX | XXX | XXX | XXX |
| Voronoi | XXX | XXX | XXX | XXX | XXX | XXX |
| J.B. Chemicals & Pharma | XXX | XXX | XXX | XXX | XXX | XXX |
| Yili Chuannig Biotech | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Hubei Jumpcan M&A Activity
Hubei Jumpcan acquired XXX companies to date.
Last acquisition by Hubei Jumpcan was on XXXXXXXX, XXXXX. Hubei Jumpcan acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Acquisitions by Hubei Jumpcan
| Acquired Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Get Verified M&A Valuation Multiples
Sign up to see revenue and EBITDA valuation multiples for 150K+ M&A deals.
Start Free TrialHubei Jumpcan Investment Activity
Hubei Jumpcan invested in XXX companies to date.
Hubei Jumpcan made its latest investment on XXXXXXXX, XXXXX. Hubei Jumpcan invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Investments by Hubei Jumpcan
| Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Hubei Jumpcan
| When was Hubei Jumpcan founded? | Hubei Jumpcan was founded in 1997. |
| Where is Hubei Jumpcan headquartered? | Hubei Jumpcan is headquartered in China. |
| How many employees does Hubei Jumpcan have? | As of today, Hubei Jumpcan has over 5K employees. |
| Is Hubei Jumpcan publicly listed? | Yes, Hubei Jumpcan is a public company listed on Shanghai Stock Exchange. |
| What is the stock symbol of Hubei Jumpcan? | Hubei Jumpcan trades under 600566 ticker. |
| When did Hubei Jumpcan go public? | Hubei Jumpcan went public in 2001. |
| Who are competitors of Hubei Jumpcan? | Hubei Jumpcan main competitors are Zhejiang Huahai, Virbac, Voronoi, J.B. Chemicals & Pharma. |
| What is the current market cap of Hubei Jumpcan? | Hubei Jumpcan's current market cap is $3B. |
| What is the current revenue of Hubei Jumpcan? | Hubei Jumpcan's last 12 months revenue is $901M. |
| What is the current revenue growth of Hubei Jumpcan? | Hubei Jumpcan revenue growth (NTM/LTM) is 6%. |
| What is the current EV/Revenue multiple of Hubei Jumpcan? | Current revenue multiple of Hubei Jumpcan is 2.2x. |
| Is Hubei Jumpcan profitable? | Yes, Hubei Jumpcan is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Hubei Jumpcan? | Hubei Jumpcan's last 12 months EBITDA is $319M. |
| What is Hubei Jumpcan's EBITDA margin? | Hubei Jumpcan's last 12 months EBITDA margin is 35%. |
| What is the current EV/EBITDA multiple of Hubei Jumpcan? | Current EBITDA multiple of Hubei Jumpcan is 6.1x. |
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.